Neuroinflammation, Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and Mycoplasma Infectious Diseases ”Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a disease characterized by chronic, profound, disabling, and unexplained fatigue.” ”Neuroinflammation is present in widespread brain areas in CFS/ME patients and was associated with the severity of neuropsychologic symptoms.” ”Evaluation of neuroinflammation in CFS/ME patients may be essential for understanding the core pathophysiology and for developing objective diagnostic criteria and effective medical treatments.” Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An 11C-(R)-PK11195 PET Study jnm.snmjournals.org/content/early/2014/03/21/jnumed.113.131045.abstract Mycoplasma Infectious Diseases is basically systemic vasculitis/neuritis. Mycoplasma Infectious Diseases is not only a cause of pneumonia but also asthma, arthritis, nephritis, meningitis, encephalitis, dermatitis, pancreatitis, hepatitis, abnormalities in blood, so on. The concept of “Mycoplasma Infectious Diseases” is broad from acute to chronic phase with a variegated condition. Therefore, it is confusing and difficult to identify the mycoplasma-infected patient among those of incurable diseases, such as autoimmune diseases, a rheumatic disease, a nervous system disorder, and hematological disorders. Regrettably, conventional diagnostic system has been helpful only for pneumonia, although it is critical turning point to find variegated Mycoplasma Infectious Diseases at an early stage for performing an effective medical protocol. Then, there was a problem to detect mycoplamsa by PCR. Because chronic Mycoplasma Infectiou Diseases is a whole body diseases based on vesculitis/neuritis, therefore, one specimin from blood or others does not reflect the state of infection quantitatively. Especially, there oftenly false negaive, even there are mycoplasmas could not detect it. From this reason, serum spcecific antibody titers are reliable marker for chronic infectious diseases. Fortunately, the cutting-edge technology based on the mycoplasma species-specific glycolipid-antigens, has made it possible to measure the amount of specific antibodies. The new technology provides a reliable marker to follow the state of Mycoplasma Infectious Diseases, monitoring the fluctuations of antibody titers. The cutting-edge technology has made it possible to measure the specific antibodies. The new diagnostics for “Mycoplasma Infectious Diseases” make it possible to monitor by measuring tiny fluctuations of antibody titers from zero. The new measuring methods, IgM, IgG, and IgA antibody amonts, using the mycoplasma species-specific glycolipid-antigens, are already established. ・Anti-Mycoplasma pneumonie-specific lipid-antigen IgM antibodies ・Anti-Mycoplasma pneumonie-specific lipid-antigen IgG antibodies ・Anti-Mycoplasma pneumonie-specific lipid-antigen IgA antibodies ・Anti-Mycoplasma fermentans-specific lipid-antigen IgM antibodies ・Anti-Mycoplasma fermentans-specific lipid-antigen IgG antibodies ・Anti-Mycoplasma fermentans-specific lipid-antigen IgA antibodies The new measuring method, IgM, IgG, and IgA antibody value is already possible. The measurement request of a sample becomes possible through clinic, hospital or medical institutions to the biggest clinical special reference laboratory. If we come to know the real cause of the illness, there is the way to remove the cause and cure it. In the case of mycoplasma it is possible. We start personalized/advanced medicine using the next generation diagnostics and concept based on the cutting edge technology.
Posted on: Fri, 03 Oct 2014 22:28:19 +0000
Trending Topics
Recently Viewed Topics
© 2015